linjc16/ctgov huggingface dataset:
Pars Plana Surgical Capsulotomy for Posterior Capsular Opacification

Study Overview
=================
Brief Summary
-----------------
Cataract is a leading cause of Global blindness. After cataract surgery nearly half of the people become blind due to posterior capsular opacification. The only solution for this problem is LASER capsulotomy. Laser machine is not available in remote areas especially in underdeveloped countries. The solution of this problem is surgical capsulotomy which can be performed any where.

Detailed Description
-----------------
posterior capsular opacification is treated by YAG laser capsulotomy. this require sophisticated technology ans specific environment which is not possible in underdeveloped countries. we describe a method in which posterior capsular opacification could be managed by using only a 27 Gauge needle through pars plana. opacified posterior capsule is under tension that is why a small puncture results in a large central opening

Official Title
-----------------
Pars Plana Surgical Capsulotomy for Posterior Capsular Opacification

Conditions
-----------------
Blindness

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with Posterior capsular opacification Both Sexes All ages Exclusion Criteria: Retinal disease Uncontrolled Glaucoma Corneal opacity

Ages Eligible for Study
-----------------
Minimum Age: 1 Year
Maximum Age: 95 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Pars Plana, Surgical Capsulotomy, Posterior capsule opacification, visual outcome, Complications
Vietnam Era Twin (VET) Registry

Study Overview
=================
Brief Summary
-----------------
To conduct a baseline survey on cardiovascular, respiratory, and other major systemic disease and risk factors in members of the Vietnam Era Twin Registry.

Detailed Description
-----------------
BACKGROUND: The Vietnam Veteran Twin Registry, maintained by the NAS-NRC, was created with funding from the Veterans Administration. Department of Defense records were searched for subjects born between 1939-1957 and having the same last name and date of birth. Follow-up of induction records determined if the subjects were twins. The registry supplemented the older World War II Veterans Twin Registry supported by the National Heart, Lung, and Blood Institute. The new registry provided an opportunity to create a resource with Black and Hispanic twins as well as whites. The new registry also included data on greater educational, socioeconomic, and lifestyle diversity than was available in the World War II Veterans Twin Registry. DESIGN NARRATIVE: During the first year a mailed questionnaire was designed which provided baseline data on family history, body size, morbidity, psychosocial characteristics, smoking, alcohol consumption, diet, physical activity, and drug use. The baseline data were used for analysis of cardiovascular, pulmonary, and blood diseases, and for follow-up. From the original survey, the Veterans Administration provided magnetic tape data on zygosity, smoking, alcohol consumption, heart, lung, and blood diseases, discharge rank, education, occupation, and family income. The questionnaire was completed by almost 8,900 individuals including over 3,000 twin pairs. The study completion date listed in this record was obtained from the Completed Date entered in the Query View Report System (QVR).

Conditions
-----------------
Cardiovascular Diseases, Blood Disease, Heart Diseases, Lung Diseases

Participation Criteria
=================
Eligibility Criteria
-----------------
No eligibility criteria

Ages Eligible for Study
-----------------
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
The Incidence of Gall Stones After Bariatric Surgery and Its Association With Weight Loss

Study Overview
=================
Brief Summary
-----------------
The incidence of Gall Stones after Bariatric surgery and its association with weight loss

Detailed Description
-----------------
Gallstone (GS) formation is common in obese patients, particularly during rapid weight loss.This study aimed to determine the incidence of GS in patients underwent bariatric surgery (BS) and the influence of weight loss on GS formation.

Official Title
-----------------
The Incidence of Gall Stones After Bariatric Surgery and Its Association With Weight Loss

Conditions
-----------------
The Incidence of Gall Stones After Bariatric Surgery and Its Association With Weight Loss

Intervention / Treatment
-----------------
* Procedure: bariatric surgery


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: (BMI) ≥35kg/m2 with one or more obesity-related comorbidities a BMI > 40 kg/m2 without coexisting medical problems Exclusion Criteria: -a conrtaindication for bariatric surgery

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: bariatric surgery|laparoscopic sleeve gastrectomy,or gastric bypass|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The incidence of Gall Stones after Bariatric surgery |  | the period between December 2018 and December 2019 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| effect of weight loss on Gall Stones formation after Bariatric surgery | effect of excess weight loss on gall stones formation after bariatric surgery | the period between December 2018 and December 2019 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
gall stones, ,bariatric surgery
Heart Rate Variability in White Coat Hypertension and Essential Hypertension

Study Overview
=================
Brief Summary
-----------------
The aim of the study is to investigate heart rate variability in patients with white coat hypertension and patients with essential hypertension.

Conditions
-----------------
Essential Hypertension, White Coat Hypertension, Healthy

Intervention / Treatment
-----------------
* Procedure: Monitoring of heart rate variability


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age 30-70 years office BP >150/95 mmHg and 24-h ambulatory BP =/>135/85 mmHg office BP >150/95 mmHg and 24-h ambulatory BP <135/85 mmHg office BP <150/95 mmHg and 24-h ambulatory BP <135/85 mmHg Exclusion Criteria: Clinical signs of disease of the heart, lungs, liver, kidneys, brain or endocrine organs neoplastic disease daily use of medicine alcohol abuse abnormal laboratory screening including blood-hemoglobin, blood-white cell count, plasma-creatinine, plasma-alanine-amino-transaminases, plasma-albumin, plasma-sodium, plasma-potassium, urinary glucose, urinary albumin; electrocardiogram pregnancy unwillingness to participate

Ages Eligible for Study
-----------------
Minimum Age: 30 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: Monitoring of heart rate variability|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Observational Study of the Preventive Trial With HIV-1 Tat Protein

Study Overview
=================
Brief Summary
-----------------
The results of the Phase I Safety and Immunogenicity Trial of Recombinant HIV-1 Tat (ISS P-001 and ISS T-001) indicate that the vaccine based on the recombinant Tat protein is safe, well tolerated and immunogenic. The present study is intended to extend the follow-up of the volunteers for additional 3 years to evaluate the persistence of the anti-Tat humoral and cellular immune response. The results of the present study will be key for the design of future phase II trials, particularly for the definition of the optimal schedule for boosting immunizations. All individuals (20) will be enrolled in a 120-weeks observational study and monitored every 24 weeks for the following 3 years. During these visits, in addition to the hematological and biochemical assessment, the anti-Tat specific humoral and cellular immune responses will be evaluated.

Official Title
-----------------
Observational Study of the Phase I Safety and Immunogenicity Trial of Recombinant HIV-1 Tat in HIV-1 Uninfected Adult Volunteers

Conditions
-----------------
Healthy Subjects

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Previous participation to the Phase I Clinical Trial ISS P-001

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To evaluate the persistence of specific immune responses, volunteers will be monitored for anti-Tat specific antibodies, anti-Tat proliferative response and in vitro γIFN and IL-4 production in response to Tat (Elispot). |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To develop test procedures in order to evaluate humoral and cellular anti-Tat immunity for future efficacy trials. |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
HIV, Tat protein, Preventive vaccine
Histologic Response to UVA and UVB Exposure During the Use of Sunscreen

Study Overview
=================
Brief Summary
-----------------
Anti-inflammatory and anti-oxidant agents have become the important ingredients in sunscreen. However, there is no histologic study about the effects of anti-inflammatory and anti-oxidative properties of sunscreen to prevent premature aging from UVA and UVB.

Detailed Description
-----------------
Premature aging can be prevented by using sunscreen. Currently, anti-inflammatory and anti-oxidant agents have become the important ingredients in sunscreen. However, there is no histologic study about the effects of anti-inflammatory and anti-oxidative properties of sunscreen to prevent premature aging from UVA and UVB.

Official Title
-----------------
Histologic Response to UVA and UVB Exposure During the Use of Sunscreen With Anti-inflammatory and Anti-oxidant Properties - A Pilot Study

Conditions
-----------------
Solar Elastosis

Intervention / Treatment
-----------------
* Other: Sunscreen


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: subjects aged 35-65 years who were scheduled for abdominoplasty the excised area should be larger than 18x10 cm2 no skin diseases or lesions on the excised area no topical treatment on excised area more than 1 month prior to this study Exclusion Criteria: pregnancy lactation have tattoo or striae distensae on abdomen

Ages Eligible for Study
-----------------
Minimum Age: 35 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Intervention Model: Single Group Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Sunscreen<br>Apply sunscreen before and after UVA and UVB irradiation | Other: Sunscreen<br>* Apply sunscreen before and after UVA and UVB irradiation<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| H&E Staining | Review difference in H&E staining in tissue biopsy before and after UVA / UVB irradiation | 2 Months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Tyrosinase Staining | Review difference in Tyrosinase staining in tissue biopsy before and after UVA / UVB irradiation to evaluate the effects of pigment darkening after UV exposure | 2 Months |
A Registered Cohort Study on SMA

Study Overview
=================
Brief Summary
-----------------
Spinal muscular atrophy (SMA) is an autosomal recessive disease that causes progressive muscle wasting and weakness due to loss of motor neurons in the spinal cord. This is a registered cohort of spinal muscular atrophy (SMA) type I，II and III in China. This study will provide further insights into the clinical course of SMA including overall survival, demographic characteristics, motor function, respiratory support, feeding and nutritional support, growth and development. The correlation of genotype and phenotype will be conducted.

Official Title
-----------------
A Registered Cohort Study on Spinal Muscular Atrophy

Conditions
-----------------
Spinal Muscular Atrophy

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with SMA types I, II and III Asymptomatic SMA carriers Relatives of SMA patients or carriers Unrelated healthy controls Participants or Parent(s)/legal guardian(s) willing and able to complete the informed consent process Exclusion Criteria: * Participants are unable to comply with trial procedures and visit schedule

Ages Eligible for Study
-----------------
Minimum Age: 1 Week
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| SMA type I<br> | |
| SMA type II<br> | |
| SMA type III<br> | |
| Asymptomatic carriers of SMA<br> | |
| Relatives of SMA patients and carriers<br> | |
| Unrelated healthy controls<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The time to death |  | From date of enrollment until the date of death from any cause, assessed up to 20years | 
| The correlation of genotype and phenotype | Genotype is defined by survival motor neuron (SMN) 2 copy number(s) and phenotype is defined by clinical types and characteristics. | From date of enrollment until the date of death from any cause, assessed up to 20years |
Effects of Hi-maize Resistant Starch on Insulin Sensitivity

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine the effects of a dietary fiber, resistant starch, on insulin sensitivity. Low insulin sensitivity is a risk factor for some diseases including type 2 diabetes and heart disease. This study will show if consuming resistant starch can help improve insulin sensitivity in overweight and obese people.

Official Title
-----------------
A Randomized, Controlled, Double-blind Crossover Study to Assess the Effects of a Dietary Fiber Ingredient, at Two Doses, on Insulin Sensitivity

Conditions
-----------------
Insulin Resistance

Intervention / Treatment
-----------------
* Other: Hi-maize starch (Low dose)
* Other: Hi-maize starch (High-dose)
* Other: Control (starch)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Stable body weight No serious health conditions Waist circumference > or = to 89 cm (females) and 102 cm (males) Exclusion Criteria: Diabetes other serious illnesses use of medications that affect outcomes BMI > or = 35.0 kg/m2

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 69 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Quadruple


Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Hi-maize starch (Low dose)|resistant starch|
|Other: Hi-maize starch (High-dose)|resistant starch|
|Other: Control (starch)|rapidly digestible starch|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| insulin sensitivity |  | 4 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Inflammatory markers, glycemia, serum lipids |  | 4 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
insulin resistance, dietary fiber, resistant starch
Study of Interleukin-21 for Metastatic Malignant Melanoma and Metastatic Kidney Cancer

Study Overview
=================
Brief Summary
-----------------
This study is being done to see if an experimental drug called recombinant interleukin-21 (rIL-21) when given to patients with stage 4 malignant melanoma or stage 4 kidney cancer is safe and has any effect on these types of cancers.

Detailed Description
-----------------
This is a phase 1 safety study. Everyone enrolled and eligible will be given rIL-21. The study has 2 parts, Part A will determine how high a dose of rIl-21 can be safely given to patients with these types of cancers. Part B will determine if the drug is of any benefit to patients with these types of cancers. Part A may have up to 7 different dose groups. Beginning with the lowest dose, 3 patients will be treated and will be watched for side effects. If the side effects are not severe, the next group of 3 patients will recieve a higher dose. This cycle is repeated until the highest tolerated dose group is found.

Official Title
-----------------
A Phase 1 Open-Label Study of the Safety and Pharmacokinetics of Recombinant Human Interleukin-21 (rIL-21) in Subjects With Metastatic Melanoma or Metastatic Renal Cell Carcinoma

Conditions
-----------------
Melanoma, Kidney Neoplasms, Metastases

Intervention / Treatment
-----------------
* Drug: Recombinant Human Interleukin-21


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 18 years and older with stage 4 metastatic malignant melanoma or stage 4 metastatic kidney cancer ECOG status of 0 or 1 Patients must have adequate liver, kidney and bone marrow function Exclusion Criteria: Known ocular melanoma Suspected or confirmed brain metastases Patient cannot have had a bone marrow transplant

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Recombinant Human Interleukin-21|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To determine the maximum tolerated dose (MTD) of rIL-21 |  |  | 
| To further characterize the safety of rIL-21 at the MTD |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Characterize pharmacokinetics of rIL-21 |  |  | 
| Evaluate immunogenicity of rIL-21 |  |  | 
| Identify clinical or biological parameters that may correlate with clinical efficacy |  |  | 
| Characterize anti-tumor effect of IL-21 |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Metastatic Melanoma, Metastatic Renal Cell Carcinoma
Emotional and Physical Health Status of Adults

Study Overview
=================
Brief Summary
-----------------
To investigate the comparison of differences between emotional and physical health status of adults in COVID-19 isolation period and controlled normalization period.

Official Title
-----------------
Emotional and Physical Health Status of Adults in Pandemia

Conditions
-----------------
Pandemic, COVID-19, Adult ALL

Intervention / Treatment
-----------------
* Other: Questionnaires


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: To speak Turkish Living in Turkey in pandemic process. Between the ages of 20-60 years. No communication problems. Being volunteer to participate in study. Exclusion Criteria: Having communication problems. Not completion the assessments.

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Questionnaires|Questionnaires about pandemia process|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pandemic Awareness Scale | To investigate the public pandemia awareness | 1 minute | 
| Chalder Fatigue Scale | A self-report scale which is used to assess perceived fatique. | 2 minutes | 
| Pittsburgh Sleep Quality Index | A self-report scale | 3 minutes | 
| EQ-5D Health-Related Quality of Life Questionnaire | This scale consists of 5 dimensions as mobility, self-care, usual activities, pain/discomfort and anxiety/depression. | 1 minute | 
| Physical Activity Score | The level of physical activity | 1 minute | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Pandemia awareness, General fatique, Quality of life, Sleep quality, Bodily pain, Status of physical activity